Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Regression of Chemotherapy-Resistant Polymerase ε (POLE) Ultra-Mutated and MSH6 Hyper-Mutated Endometrial Tumors with Nivolumab.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Dec 2016

Santin Alessandro D, Bellone Stefania, Buza Natalia, Choi Jungmin, Schwartz Peter E, Schlessinger Joseph, Lifton Richard P

Abstract excerpt

PURPOSE: The management of endometrial carcinoma no longer amenable to treatment with surgery or radiotherapy has not improved significantly with modern chemotherapy. Alternative therapeutic options are desperately needed. EXPERIMENTAL DESIGN: We describe 2 heavily pretreated patients with recurrent disease refractory to surgery, radiotherapy, and chemotherapy who were treated with the anti-PD-1 immune checkpoint...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Polymerase II

Share to Endometrial Neoplasms

Share to Mutation

Share to Neoplasm Recurrence, Local

Share to Nivolumab

Share to Programmed Cell Death 1 Receptor

Source

Open in PubMed Open full text

Identifiers

PMID: 27486176
DOI: 10.1158/1078-0432.CCR-16-1031
PMCID: PMC5135588

Genes

MSH6
POLE

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Regression of Chemotherapy-Resistant Polymerase ε (POLE) Ultra-Mutated and MSH6 Hyper-Mutated Endometrial Tumors with Nivolumab.PMID 27486176Read ↗

Polymerase ε (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro.Semantic proximity Read ↗

Checkpoint inhibitors in endometrial cancer: preclinical rationale and clinical activitySemantic proximity Read ↗

A novel somatic mutation in POLE exonuclease domain associated with ultra-mutational signature and MMR deficiency in endometrial cancer: a case reportSemantic proximity Read ↗

Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer.Semantic proximity Read ↗

Tumor genotype and immune microenvironment in POLE-ultramutated and MSI-hypermutated Endometrial Cancers: New candidates for checkpoint blockade immunotherapy?Semantic proximity Read ↗

A novel somatic mutation in POLE exonuclease domain associated with ultra-mutational signature and MMR deficiency in endometrial cancer: a case report.Semantic proximity Read ↗

Tumor Mutational Burden Guides Therapy in a Treatment Refractory POLE-Mutant Uterine Carcinosarcoma.Semantic proximity Read ↗

A Pilot study of POLE mutations in endometrial cancer and its clinicopathological correlation with Microsatellite Instability and P53 mutationsSemantic proximity Read ↗

The advent of immune checkpoint inhibition for the treatment of patients with primary advanced or recurrent dMMR/MSI high endometrial cancer in 2025.Semantic proximity Read ↗

Phenotype of POLE-mutated endometrial cancerSemantic proximity Read ↗

Adjuvant Treatment for POLE Proofreading Domain-Mutant Cancers: Sensitivity to Radiotherapy, Chemotherapy, and Nucleoside Analogues.Semantic proximity Read ↗

The P286R mutation of DNA polymerase ε activates cancer-cell-intrinsic immunity and suppresses endometrial tumorigenesis via the cGAS-STING pathway.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.